A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients.
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2015
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record